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Background
Bone marrow fibrosis in patients with myelodysplastic syndrome is associated with a poor out-
come, but whether the outcome after allogeneic stem cell transplantation is related to the
degree of bone marrow fibrosis is unknown. 
Design and Methods
Patients with myelodysplastic syndrome and known bone marrow histology (n=721) who
underwent hematopoietic stem cell transplantation were classified according to the degree of
bone marrow fibrosis into those without fibrosis (n=483), those with mild or moderate fibrosis
(n=199) and those with severe fibrosis (n=39) and analyzed regarding engraftment, treatment-
related mortality, relapse and survival.
Results
The degree of fibrosis was not associated with disease status or abnormal cytogenetics. The
cumulative incidence of engraftment achieved at day +30 in non-fibrotic patients was 93% and
was significantly lower in those with mild or moderate fibrosis (89%) and severe fibrosis (75%)
(P=0.009). Neutrophil engraftment occurred later in patients with mild or moderate fibrosis and
severe fibrosis than in patients without fibrosis (median 17 versus 20 versus 16 days, respectively;
P=0.002). The cumulative incidence of relapse at 3 years was significantly higher in patients with
severe fibrosis than in those with a lesser degree of fibrosis or no fibrosis (47% versus 28% versus
27%, respectively; P=0.04), resulting in comparable 3-year disease-free survival rates in patients
without fibrosis and in those with mild or moderate fibrosis (42% versus 38%, respectively) but
a lower disease-free survival rate in those with severe fibrosis (18%; P=0.002). Severe fibrosis
remained an independent factor for reduced survival (hazard ratio, 1.9; P=0.006).
Conclusions
Among patients with myelodysplastic syndromes, only severe fibrosis affects survival after
hematopoietic stem cell transplantation while patients with mild or moderate fibrosis have an
outcome comparable to that of patients without bone marrow fibrosis.
Key words: bone marrow fibrosis, allogeneic stem cell transplantation, myelodysplastic syn-
dromes, engraftment.
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Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous
group of clonal hematopoietic diseases, for which several
scoring systems have been developed to predict prognosis.
These scoring systems incorporate information on cytoge-
netics, number of cytopenias and number of blasts
(International Prognostic Scoring System, IPSS),1 or these
variables integrated with transfusion dependency (WHO
classification-based Prognostic Scoring System, WPSS).2
Several studies have shown that other factors, such as
bone marrow fibrosis, provide additional information
associated with poor outcome in MDS patients.3-7
Allogeneic stem cell transplantation is now more fre-
quently used as a curative treatment approach for MDS.
The introduction of so-called dose-reduced conditioning
regimens allows transplantation of patients up to the age
of 70 years. The major risk factors for outcome after allo-
geneic stem cell transplantation for MDS are certain cyto-
genetic characteristics, number of blasts, status of the dis-
ease and age of the patient. Information about the impact
of bone marrow fibrosis on outcome after allogeneic stem
cell transplantation in patients with MDS is only limited.8
Here we report on 721 MDS patients with known bone
marrow fibrosis status, determined by bone marrow his-
tology, who received an allogeneic stem cell transplant and
whose data were reported to the European Group for
Blood and Marrow Transplantation (EBMT).
Design and Methods
We collected data from 721 patients with MDS and known
bone marrow histology at diagnosis who underwent allogeneic
stem cell transplantation between 1978 and 2009. The data were
extracted from the EBMT registry of patients with MDS or sec-
ondary acute myeloid leukemia (sAML). In this study we included
only patients diagnosed with MDS. Patients with primary
myelofibrosis or overlap syndrome, i.e. with MDS/myeloprolifer-
ative syndrome (MPS) were excluded. Out of these 721 patients,
483 were classified as not having fibrosis, 199 were classified as
having mild or moderate fibrosis and 39 as having severe fibrosis.
The degree of fibrosis was determined by the hematopathologist
at each patient’s transplant center. As shown in detail in Table 1
there were no significant differences between the three groups of
patients with respect to age, gender, therapy-related MDS/AML,
stem cell source, conditioning regimen, donor, disease status, cyto-
genetics, time from diagnosis to transplant, transplant period and
median number of blasts at transplantation. The only difference
between the groups was that significantly more patients with
mild/moderate fibrosis were positive for cytomegalovirus
(P=0.04).
Statistical analysis
The characteristics of the patients were expressed as medians
and ranges for continuous variables and frequencies for categorical
variables. Categorical data were compared by the c2 test, while
continuous variables were compared using the Kruskal-Wallis test.
Survival curves were either estimated using the Kaplan-Meier
method (if no competing risk were involved), and then the signif-
icance of the log-rank test was used, or computed in a competing
risk framework (to estimate the cumulative incidence of a specific
event in the case of competing risks). For multivariate analyses the
Cox model was used to estimate hazard ratios and cause-specific
hazards but in the case of competing risks, the curve estimates of
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Table 1. Patients’ characteristics (n=721) according to bone marrow
fibrosis.
Known fibrosis                None             Mild /         Severe           P
(n=721)                         (n=483)         moderate        (n=39)         value
                                                             (n=199)
Male                                         60 %                   57 %                54 %                0.7
Female                                    40 %                   43 %                46 %
t-MDS / AML                           10 %                   11 %                15 %                0.6
Stem cell source
bone marrow                      36 %                   34 %                35 %
peripheral blood               62 %                   63 %                59 %
cord blood                          1 %                    1 %                 3 %                0.4
bone marrow                     1 %                   1 %                3 %
+ peripheral blood
missing                                   –                      1 %                   –                     
Conditioning
standard                              64 %                   70 %                77 %
reduced                               36 %                   30 %                23 %               0.12
TBI-containing regimen      44 %                   44 %                56 %               0.34
HLA-identical sibling           58 %                   56 %                59 %                  
Syngeneic                               0.6 %                  2.5 %                0 %
Matched – other relative     1 %                    2 %                0 %
Matched unrelated            29.4 %               27.5 %               33 %               0.07
Mismatched related            4 %                   3 %                3 %                  
Mismatched unrelated        7 %                   9 %                5 % 
Related                                    64 %                   64 %                62 %
Unrelated                               36 %                   36 %                38 %               0.97
Donor sex
male                                      61 %                   56 %                56 %
female                                  39 %                   44 %                44 %                0.4
CMV-positive serostatus    61 %                   71 %                64 %               0.04
of recipient
Disease status at diagnosis 
(n=721)
RA/RARS                              36 %                   39 %                31 %                0.7
RAEB                                    43 %                   43 %                48 %
RAEB-t                                  21 %                   18 %                21 %
Disease status at 
transplant (n = 605)
RA/RARS                              28 %                   29 %                22 %
RAEB                                    40 %                 42.5 %               48 %
RAEB-t                                  24 %                 23.5 %               26 %                0.8
sAML                                    8 %                   5 %                 4 %  
Cytogenetics (n = 706)
normal                                              43 %            42 %           29 %
abnormal                                          49 %            51 %           58 %             0.40
not done                                           8 %            7 %           13 %
Time from diagnosis to SCT
<6 months                                       35 %            32 %           31 %
6–12 months                                   33 %            33 %           31 %              0.9
>12 months                                     32 %            35 %           38 %
IPSS at transplantation(n=294)    n=191        n= 103
                                                                            (incl.  severe
                                                                                fibrosis)
low                                                       8%               4%
intermediate 1                                 39%             39%                                  0.5  
intermediate 2                                 24%             22%                
high                                                    29%             35%                                     
Median age of                                       49                50               47               0.43
recipient (range)                           (18–69)     (18–67)     (23–70)             
Median age of                                      44                44               44               0.70
donor (range)                                  (1–74)      (11–69)      (5–66)              
Median number of blasts               n=149          n=67           n=9             0.35
in bone marrow (range)                   10%            12%            10% 
                                                            (5–90%)    (5–80%)   (6–70 %)
continued on the next page.
the Cox model were not used since they are inappropriate in such
cases. For survival analysis the event was “death from any cause”
and the time interval was that from transplantation to the date of
this event (uncensored) or the last follow-up date (censored),
whichever came first. For disease-free survival the event was
defined as “relapse or progression or death from any cause” and
the time interval was again from transplantation onwards. For
treatment-related mortality the event was defined as “death relat-
ed to transplantation”; the time interval was again calculated from
transplantation until this event (uncensored) or the last follow-up
of the patient (censored), which implies that patients who died
from other causes were censored at time of death. Engraftment
was defined as a leukocyte count of more than 1.0¥109/L for 3 con-
secutive days. It was considered that no engraftment had occurred
if engraftment was not found at day 30 after transplantation. The
cumulative incidence method was used to estimate the incidence
of both transplant-related mortality and relapse to account for
competing events. The following factors were included in the uni-
variate analysis: sex of the patient, sex of the donor, age, HLA
match, disease status, number of blasts, cytogenetics, bone mar-
row fibrosis at diagnosis, transplant period, donor source and time
from diagnosis to transplantation. Factors that had a P value of less
than 0.1 univariately were included in multivariate Cox regression
model (forward elimination) analysis using the hazard ratios esti-
mated in Cox models. Calculations were performed in SPSS ver-
sion 15 (SPSS, Chicago, IL, USA). The competing risk analyses
were done with the ACCorD (V. Gebski, National Health and
Medical Research Council, Clinical Trial Center, University of
Sydney, Australia).
Results
Treatment-related mortality
The cumulative incidence of treatment-related mortality
for the study population at 1 year was 28% (95% CI, 24-
32%). There was no difference in treatment-related mor-
tality at 1 year between patients without fibrosis, those
with mild/moderate fibrosis and those with severe fibrosis
patients (30% and 31% versus 26%, respectively; P=0.3).
Factors that were significantly related with higher treat-
ment-related mortality were HLA-mismatch (HR, 1.65;
P=0.008), blast content in bone marrow as a continuous
variable (HR, 1.01; P=0.03), bone marrow as the source of
stem cells (HR, 1.34; P=0.03). Use of a reduced-intensity
conditioning regimen was associated with lower trans-
plant-related mortality (HR 0.64, P=0.006). There was also
a significant improvement in transplant-related mortality
for patients transplanted in more recent years (P=0.007)
(Table 2). In a multivariate analysis the factors significantly
related with higher transplant-related mortality were not
being in complete remission (HR, 2.05; P<0.001), HLA
mismatch (HR, 1.68; P=0.007) and standard conditioning
(HR, 1.85; P=0.001) (Table 3).
Relapse
The cumulative incidence of relapse for the study popu-
lation at 3 years was 29% (95% CI, 25-33%). Factors sig-
nificantly related to a higher incidence of relapse were
severe bone marrow fibrosis (HR, 2.33; P=0.003), abnor-
mal cytogenetics (HR, 1.73; P<0.001), donor’s age as a con-
tinuous variable (HR, 1.01; P=0.02), number of blasts at
the time of transplantation (HR, 1.02; P=0.003), T-cell
depletion in vivo and ex vivo (HR: 1.61, P=0.03), and disease
status (refractory anemia with excess blasts [RAEB]: HR,
1.61; RAEB in transformation [RAEB-t]: HR, 2.08; sAML:
HR, 2.17; P=0.006). Furthermore, there was a trend for
higher relapse incidence among patients who received
reduced-intensity conditioning (HR, 1.29; P=0.09) and
those for the whom the source of stem cells was peripher-
al blood (HR, 1.31; P=0.08) (Table 2). In a multivariate
analysis the following factors remained significant:
advanced disease status, defined as RAEB, RAEB-t or
sAML (P=0.004), abnormal cytogenetics (HR, 1.96;
P<0.0001) and donor’s age (HR, 1.02; P=0.02) (Table 3).
Disease-free survival
The 3-year estimated disease-free survival for the study
population was 40% (95% CI: 36-44%). In a univariate
analysis the following factors were significantly associated
with poor disease-free survival: not  being in complete
remission at the time of transplantation (HR, 1.52;
P=0.001), high blast percentage at transplantation (HR,
1.02; P<0.001), abnormal cytogenetics (HR, 1.44; P=0.001)
and bone marrow fibrosis (mild/moderate: HR, 1.13;
severe: HR, 1.88; P=0.003). Furthermore, there was a trend
for reduced disease-free survival according to disease stage
(RAEB: HR, 1.45; RAEB-t: HR, 1.44; sAML: HR, 1.31;
P=0.06) and HLA-mismatched transplantation (HR, 1.31;
P=0.07) (Table 2). In a multivariate analysis, disease stage
(P=0.004), severe fibrosis (HR, 1.73; P=0.02), abnormal
cytogenetics (HR, 1.32; P=0.02) and not being in complete
remission before transplantation (HR, 1.85, P<0.001)
remained statistically significant (Table 3).
Overall survival
The 3-year estimated overall survival for the study pop-
ulation was 45% (95% CI, 41-49%). Disease stage (RAEB:
HR, 1.54; RAEB-t: HR, 1.51; sAML: HR, 1.30; P=0.03), not
being in complete remission at transplantation (HR, 1.57;
P=0.001), abnormal cytogenetics (HR, 1.33; P=0.01), HLA-
mismatch (HR, 1.50; P=0.007), blast percentage at trans-
plantation (HR, 1.01; P=0.001) and bone marrow fibrosis
(mild/moderate: HR, 1.13; severe: HR, 1.94; P=0.002) were
significant factors in the univariate analysis (Table 2). In a
multivariate analysis disease status (P=0.005), severe fibro-
sis (HR, 1.90; P=0.006), not being in complete remission at
transplantation (HR, 1.88; P<0.001) and HLA-mismatch
Allogeneic SCT for MDS with bone marrow fibrosis 
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continued from previous page. 
Median interval between                 7.7               8.3              8.2              0.75
diagnosis and SCT: months         (0.3–259)   (1.6–92)   (2.1–122)
(range)                                                     
Median follow-up in                            37                35               12               0.71
months (range)                               (1–262)     (1–170)      (4–79)              
T-cell depletion (n = 703)
no                                                       45%             54%            50%
in vivo                                               36%             29%            32%                 
ex vivo                                               8%             9%            2%             0.22
in vivo + ex vivo                             11%             8%            16%
Performance status 
(n = 437)
good                                                   94%             91%            92%             0.48 
poor                                                    6%             9%            8%
Remission status (n=686)            n=467         n=183         n=36                
complete remission                      29%             20%            25%             0.06
no complete remission                 71%             80%            75%
TBI: total body irradiation; CMV: cytomegalovirus; RA: refractory anemia; RARS: refrac-
tory anemia with ringed sideroblasts; SCT: stem cell transplantation.
(HR, 1.48; P=0.02) remained independent factors associat-
ed with poor survival (Table 3).
Results according to grade of bone marrow fibrosis
The cumulative incidence of engraftment achieved at
day +30 in patients without fibrosis was 93% and was sig-
nificantly lower in those with mild/moderate (89%) or
severe (75%) bone marrow fibrosis (P=0.009).
Furthermore, in those patients who engrafted successfully,
the median time to leukocyte engraftment (white cell
count > 1¥109/L) was 16 days in patients with no fibrosis,
17 days in patients with mild/moderate fibrosis and 20
N. Kröger et al.
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Table 2. Univariate analysis of relapse and therapy-related mortality (TRM), overall survival (OS) and disease-free survival (DFS).                
                                                      Relapse                    P                     TRM                 P                  OS                 P                   DFS                      P
                                                  HR (95% CI)              value            HR (95% CI)        value       HR (95% CI)       value          HR (95% CI)             value
Reduced intensity conditioning           1.29                          0.09                        0.64                  0.006                 0.82                 0.09                     0.91                         0.39
                                                              (0.97–1.73)                                            (0.47–0.88)                               (0.66–1.03)                                (0.74–1.13)
Abnormal cytogenetics                          1.73                       < 0.001                       −                        −                    1.33                 0.01                     1.44                        0.001
                                                               (1.27–2.34)                                                                                                (1.07–1.65)                                (1.17–1.77)
Donor age                                                 1.01                          0.02                           −                        −                      −                      −                          −                              −
                                                               (1.00–1.03)                                                       
Bone marrow fibrosis
none                                                           1                            0.003                          1                     0.153                    1                   0.002                       1                           0.003
mild/moderate                          1.002 (0.73–1.39)             0.990            1.25 (0.93–1.67)       0.134      1.21 (0.96–1.51)      0.103         1.13 (0.91–1.40)             0.269
severe                                          2.33 (1.42–3.82)              0.001            1.51 (0.87–2.63)       0.140      1.94 (1.32–2.86)      0.001         1.88 (1.30–2.72)             0.001
Blasts (in bone marrow)           1.02 (1.07–1.03)              0.003            1.01 (1.00–1.02)        0.03       1.01 (1.01–1.02)      0.001         1.02 (1.01–1.02)            <0.001
Not in complete remission        1.22 (0.88–1.68)               0.23             1.93 (1.35–2.77)      <0.001    1.57 (1.22–2.03)      0.001         1.52  (1.20–1.93)             0.001
Disease
RA/RARS                                                    1                            0.006                          1                     0.275                    1                   0.034                       1                           0.063
RAEB                                           1.61 (1.05 – 2.48)             0.031           1.34 (0.95 – 1.90)      0.096     1.54 (1.15 – 2.06)    0.003        1.45 (1.10 – 1.90)            0.007
RAEB-t                                        2.08 (1.34 – 3.24)             0.001           1.03 (0.69 – 1.56)      0.873     1.51 (1.10 – 2.06)    0.010        1.44 (1.07 – 1.93)            0.016
sAML                                           2.17 (1.17 – 4.01)             0.014           0.79 (0.39 – 1.60)      0.507     1.30 (0.80 – 2.13)    0.287        1.31 (0.83 – 2.07)            0.246
other/unknown                         2.21 (1.37 – 3.55)             0.001           1.03 (0.66 – 1.62)      0.892     1.56 (1.11 – 2.20)    0.011        1.48 (1.07 – 2.04)            0.018
HLA mismatch                              0.94 (0.58 – 1.53)              0.81            1.65 (1.14 – 2.38)      0.008     1.50 (1.12 – 2.02)    0.007        1.31 (0.98 – 1.75)             0.07
Stem cell source: PB                  1.31 (0.97 – 1.77)              0.08        BM: 1.34 (1.02 – 1.76)   0.03                    −                      −                          −                              −
SCT in year
>2001                                                        −                               −                            1.0                   0.007                   −                      −                          −                              −
1998–2001                                                                                                    1.20 (0.86 – 1.66)      0.281
<1998                                                                                                           1.72 (1.23 – 2.40)      0.002
T-cell depletion
no                                                               1                             0.03                          1.0                   0.055                   −                      −                          −                              −
in vivo                                         1.43 (1.04 – 1.96)              0.03            0.70 (0.50 – 0.98)      0.040
ex vivo                                        0.85 (0.48 – 1.50)              0.57            1.16 (0.74 – 1.82)      0.519
in vivo + ex vivo                      1.61 (1.04 – 2.50)              0.03            1.25 (0.82 – 1.90)      0.309
RA: refractory anemia; RARS: refractory anemia with ringed sideroblasts; SCT: stem cell transplantation; PB: peripheral blood.
Table 3. Significant factors in multivariate analysis for relapse, transplant-related mortality (TRM), disease-free survival (DFS), and overall survival
(OS).
                                       Relapse (n=543)             P             TRM (n=616)            P           DFS (n=562)            P               OS (n=562)               P
                                         HR (95 % CI)             value          HR (95 % CI)         value        HR (95 % CI)         value           HR (95 % CI)            value
Disease status
RA/RARS                                          1                            0.004                        −                          −                         1                      0.004                          1                          0.005
RAEB                                  1.74 (1.05–2.88)              0.033                                                                   1.56 (1.15–2.1)          0.004           1.70 (1.23– 2.34)            0.001
RAEB-t                                2.26 (1.36–3.77)              0.002                                                                   1.97 (1.38–2.8)          0.000           1.97 (1.36– 2.86)            0.000
sAML                                   2.55 (1.25–5.17)              0.010                                                                   1.48 (0.86–2.5)          0.157           1.53 (0.87– 2.69)            0.141
other/unknown                 2.66 (1.54–4.58)              0.000                                                                  1.60 (1.09–2.32)         0.015           1.60 (1.08– 2.39)            0.021
Abnormal cytogenetics     1.96 (1.41 – 2.72)          <0.0001                     −                          −          1.32 (1.05 – 1.65)         0.02                          −                             −
Not CR prior to SCT                        −                       −          2.05 (1.39 – 3.04)      < 0.001    1.85 (1.37 – 2.50)     < 0.001         1.88 (1.38 – 2.57)         < 0.001
HLA mismatch                                 −                       −             1.68.(1.15 – 2.46)        0.007                −                   −           1.48.(1.06 – 2.07)            0.02
Standard conditioning                     −                       −          1.85 (1.28 – 2.68)        0.001                     −                   −                      −                      −
Age of donor                        1.02 (1.00 - 1.03)             0.02                        −                    −                        −                   −                      −                      −
Bone marrow fibrosis
none                                                                                                                                                                       1                      0.05                       1                        0.02
mild/moderate                                                                                                                                       1.05 (0.82 – 1.34)         0.73            1.10 (0.85 – 1.42)           0.487
severe                                                                                                                                                     1.73 (1.11 – 2.69)         0.02            1.90 (1.20 – 3.00)           0.006
RA: refractory anemia; RARS: refractory anemia with ringed sideroblasts; CR: complete remission; SCT: stem cell transplantation.
days in patients with severe fibrosis (P=0.002) (Figure 1).
There were no significant differences in acute and chronic
graft-versus-host disease between the three groups. The
incidence of relapse at 3 years was significantly higher in
the group with severe fibrosis than in those with
mild/moderate or no fibrosis (47% versus 27% versus 28%,
respectively; P=0.04), resulting in a significantly lower dis-
ease-free survival at 3 years (18% versus 38% versus 42%;
P=0.002) and, likewise, a significantly lower overall sur-
vival at 3 years (21% versus 40% versus 49%; P=0.002)
(Table 4).
Results according to the International Prognostic
Scoring System score and fibrosis
To evaluate the impact of fibrosis and the IPSS score, we
correlated fibrosis and IPSS score in 294 patients for
whom the IPSS score at transplantation was known. The
degree of fibrosis was well balanced in patients with all
IPSS scores (data not shown). The estimated 3-year overall
survival rates for patients with intermediate-1-risk MDS
with and without fibrosis were 43% and 52%, respective-
ly (P=0.6). The estimated 3-year overall survival rates for
patients with intermediate-2-risk MDS with and without
bone marrow fibrosis were 42% and 48%, respectively
(P=0.6), and those for high-risk patients also did not differ
significantly between patients with (22%) and without
bone marrow fibrosis (33%, P=0.4).
Discussion
Here we analyzed the impact of bone marrow fibrosis
on outcome after allogeneic stem cell transplantation in
MDS patients reported to the EBMT registry. We included
only patients diagnosed with MDS, while those with pri-
mary myelofibrosis or overlap syndrome (MDS/MPS)
were excluded from this analysis. The prognostic impact
of bone marrow fibrosis in MDS patients has come into
focus and several studies have confirmed a negative
impact of fibrosis on survival3-7 with some authors sug-
gesting that MDS with fibrosis could be considered as a
distinct entity.9-11 Although bone marrow fibrosis is not
included in the current prognostic risk scores such as the
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Table 4. Results of stem cell transplantation in MDS patients without
bone marrow fibrosis, with mild or moderate fibrosis and with severe
fibrosis.
Fibrosis                                   None         Mild/          Severe    P value
                                                               moderate
Cumulative                                      93 %             89 %                75 %         0.009
incidence of                                 (91-95)        (85-93)           (61-89)
engraftment at day +30
Median days to leukocyte              16                 17                    20           0.002
engraftment (>1.0¥109 /L)         (1-69)          (7-47)            (11-34)
(range)
Acute GVHD grade II - IV              31%              35%                 31%           0.49
Chronic GVHD n = 450
none                                              45 %             35 %                56 %
limited                                           26 %             28 %                12 %           0.13
extensive                                      29 %             37 %                32 %
1-year therapy-related                  26 %              30%                 31%
mortality                                        (22-30)        (24-36)           (17-45)        0.34
3-year cumulative                          28 %             27 %                  47 
incidence of relapse                  (24-32)        (21-33)           (29-65)        0.04
3-year disease-free survival         42 %             38 %                18 % 
                                                         (36-48)        (30-46)            (4-32)        0,002
3-year oveall survival                     49 %             40 %                21 % 
                                                        (43-55)        (32-48)            (7-35)        0.002
GVHD: Graft-versus-host disease, in brackets: 95% confidence interval.
Figure 1. Cumulative incidence of (A) engraftment, (B) treatment-
related mortality (TRM), and (C) relapse according bone marrow
fibrosis grading.
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IPSS1 and WPSS,2 some investigators recommend more
aggressive treatment for patients with bone marrow fibro-
sis than either the IPSS or WPSS score would dictate.7
When we analyzed the outcome of patients according to
IPSS and whether or not they had bone marrow fibrosis,
we found no significant differences in overall survival.
Given the low number of patients with severe fibrosis this
group of patients could not be analyzed separately regard-
ing IPSS score. The prognostic impact of bone marrow
fibrosis in MDS patients who underwent allogeneic stem
cell transplantation has not been studied in detail. In one
study no differences in overall survival, relapse-free sur-
vival and non-relapse mortality were found between
patients with or without bone marrow fibrosis. However,
when patients with intermediate-2-risk or high-risk MDS
were studied separately, the presence of bone marrow
fibrosis was associated with a negative impact on out-
come.8
In our study, based on a large cohort of patients, we
found that while patients with mild or moderate bone
marrow fibrosis had a similar outcome to those without
bone marrow fibrosis after allogeneic stem cell transplan-
tation, patients with severe bone marrow fibrosis had a
significantly worse survival. Our results are consistent
with reports indicating a lower engraftment rate as well as
delayed leukocyte engraftment for patients with increased
bone marrow fibrosis,8,12 although they contrast with
those of other investigators who did not find a difference
in engraftment for patients with bone marrow fibrosis.13 In
this EBMT study the difficulties in engraftment resulted
only in a trend to a higher treatment-related mortality.
Notably, bone marrow fibrosis did not influence the inci-
dence of acute or chronic graft-versus-host disease.
Regarding relapse incidence we observed a significantly
higher risk of relapse in the group with severe fibrosis, but
only in univariate analysis. In multivariate analysis for
relapse and treatment-related mortality, fibrosis was not a
significant independent risk factor. However, in a multi-
variate analysis for disease-free and overall survival severe
fibrosis remained a significant independent risk factor. 
Some authors interpret bone marrow fibrosis in MDS
patients as a more malignant subtype of MDS and found
some correlation with multilineage dysplasia or excess of
blasts,6 but in our population of patients mild/moderate
and severe bone marrow fibrosis were seen in all cate-
gories and disease stages of MDS, and were not associated
with other known risk factors such as disease status,
abnormal cytogenetics, age or number of blasts.6,8 The
comparable interval between diagnosis and transplanta-
tion of about 8 months further suggests that MDS patients
with bone marrow fibrosis are not in a more advanced
stage. The observed risk factors for relapse such as age,
disease status and abnormal cytogenetics, as well as the
risk factors for overall survival, such as disease status, not
being in complete remission at transplantation and HLA-
mismatch, show that this study population was not a
selected cohort and represented a common MDS popula-
tion. 
The pathogenesis of fibrosis in MDS patients is unclear.
The bone marrow fibrosis may lead to cytopenia and mar-
row insufficiency. It remains to be determined whether
overproduction of cytokines, such as platelet-derived
growth factor-α or -b, transforming growth factor-b1 or
basic fibroblast growth factor by malignant or inflamma-
tory cells, is involved, as it is in other diseases.14,15 Also,
while MDS with bone marrow fibrosis can share some
features with primary myelofibrosis, cytogenetic features
and molecular markers differ substantially between the
two diseases. Buesche found dyserythropoiesis and
greater than 50% micromegakaryocytes with a hypolobu-
lated round nucleus exclusively in MDS patients, while
more than 10% giant megakaryocytes were found in
100% of the patients with primary myelofibrosis and in
only 6% of the MDS-fibrosis patients. Furthermore,
splenomegaly, leukocytosis and thrombocytosis were
more common in primary myelofibrosis while thrombo-
cytopenia and anemia were more often seen in MDS-
fibrosis patients.6 In the same trial the investigators
observed a correlation between  bone marrow fibrosis and
multilineage dysplasia, severe thrombocytopenia, a higher
probability of clonal karyotype abnormalities and a higher
percentage of blasts in peripheral blood and a shorter sur-
vival of MDS fibrosis patient. The prognostic significance
was independent of the IPSS. In a similar study Della Porta
detected moderate to severe bone marrow fibrosis in 17%
of the MDS patients and fibrosis was associated with mul-
tilineage dysplasia, poor-risk cytogenetic abnormalities
and high transfusion requirement. Those patients had a
poor outcome irrespectively of the presence of an excess
N. Kröger et al.
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Figure 2. Probability of (A) disease-free survival and (B) overall sur-
vival after stem cell transplantation (SCT) according to degree of
bone marrow fibrosis.
A
B
1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
Pr
ob
ab
ili
ty
 o
f d
is
ea
se
-fr
ee
 s
ur
vi
va
l
Pr
ob
ab
ili
ty
 o
f o
ve
ra
ll 
su
rv
iv
al
0.00 50.00 100.00 150.00 200.00 250.00 300.00
Months after SCT
0.00 50.00 100.00 150.00 200.00 250.00 300.00
Months after SCT
none
none
severe
severe
mild/mod
mild/mod
of blasts.7 Since our study is a retrospective registry study
and no central review was performed to confirm the diag-
nosis of MDS, it cannot be excluded that some cases were
misdiagnosed as MDS and should have been classified as
MPS or MDS/MPS overlap syndrome. Unfortunately, data
about spleen size or molecular markers such as the JAK2
mutation are only available for a small minority of the
patients, but some indirect facts support the belief that the
study population was a MDS population. First, the time
from diagnosis to transplantation was only 8 months,
which is substantially shorter than that observed in
patients with myelofibrosis. Furthermore, the survival of
myelofibrosis patients with usually severe fibrosis is
reported to be about 50% after allogeneic stem cell trans-
plantation, and substantially better than the observed
18% disease-free survival in patients with severe bone
marrow fibrosis in the current study.16,17
We conclude that bone marrow fibrosis in MDS patients
influences engraftment after allogeneic stem cell trans-
plantation but that only severe bone marrow fibrosis
affects survival because of a higher risk of relapse, while
MDS patients with mild or moderate bone marrow fibro-
sis have an outcome comparable to that of MDS patients
without bone marrow fibrosis.
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